EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model
Frontiers in Pharmacology · 10.07.2025 · 16
DOI: 10.3389/fphar.2025.1621030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.07.2025. Verfasst von Karthik Dhananjayan und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Laboratory of Vascular Signaling Research, MIGAL-Galilee Research Institute, Ltd., Kiryat Shmona, Israel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Innovation Authority.
Abstract (Originalsprache)
Background
Pulmonary arterial hypertension (PAH) is a progressive pulmonary arteriopathy characterized by vascular remodeling and subsequent increases in pulmonary vascular resistance, which further develops into right ventricular failure and death. Currently, PAH management targets pulmonary vasoconstriction, though there is an unmet medical need to develop therapeutics focusing on pulmonary vascular remodeling. Recently, we reported that 5,6-diHETE lactone (EPA-L, a stable metabolite of the EPA fatty acid) elicits vasodilation and blood-pressure-lowering effect in 5/6 nephrectomy hypertensive rats and vasodilation in human arterioles by an endothelial-dependent mechanism.
Aim
We aimed to investigate the effect of EPA-L in a monocrotaline (MCT)-induced rat model of PAH.
Methods
Sprague-Dawley Rats were divided into four groups; 3 received MCT (60 mg/kg, s. c.), and the control group was treated with saline. After 3 weeks, MCT rats were treated with saline, 0.3 or 3.0 mg/kg EPA-L, for five consecutive days. Finally, all animals were sacrificed upon functional, hematological, and histological evaluations.
Results
EPA-L administration (i.v.) significantly reduced mean pulmonary arterial pressure (p < 0.05), echocardiographic pulmonary artery time-to-peak (p < 0.05), arterioles intimal-media thickness (p < 0.05) compared to the MCT group. Blood chemistry resulted in a significant reduction in hypoxic indices following the EPA-L administration, but it did not reduce the macrophage infiltration to the lungs and indicators of systemic inflammation, such as neutrophil count and % lymphocyte.
Conclusion
In addition to the dilation properties, EPA-L attenuates MCT-induced pulmonary hypertension by improving hemodynamic parameters, and vascular modification. Therefore, EPA-L may act as a promising candidate for treating PAH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Laboratory of Vascular Signaling Research, MIGAL-Galilee Research Institute, Ltd., Kiryat Shmona, Israel.
- Department of Nutrition Sciences, Tel-Hai College, Kiryat Shmona, Israel.
- The Cardiovascular Research Laboratory, Research Institute, Galilee Medical Center, Nahariya, Israel.
- The Cardiology Department, Galilee Medical Center, Nahariya, Israel.
- The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Department of Pathology, Galilee Medical Center, Nahariya, Israel.
Förderung
- Israel Innovation Authority
Zitieren
APA
Dhananjayan, K., Ertracht, O., Atar, S., Livoff, A., Shehadeh, M., & Szuchman-Sapir, A. (2025). EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1621030
Vancouver
Dhananjayan K, Ertracht O, Atar S, Livoff A, Shehadeh M, Szuchman-Sapir A. EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1621030
BibTeX
@article{Dhananjayan2025,
author = {Dhananjayan, Karthik and Ertracht, Offir and Atar, Shaul and Livoff, Alejandro and Shehadeh, Mona and Szuchman-Sapir, Andrea},
title = {EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1621030}
}
EUVIMED